Skye Bioscience, Inc. (SKYE) — research page
US · us-cm-kg/NASDAQ/SKYE · as of 2026-11-08
Identity and listing
The issuer is Skye Bioscience, Inc., listed on NASDAQ under the ticker SKYE. Its ISIN is not on the record and its LEI is not on the record. Its security type is Corporate, its sector is 2834 Pharmaceutical Preparations, and its jurisdiction is the United States, Nevada. Its segment is not on the record. Its status is listed, not halted.
| field | value | source · read date |
|---|---|---|
| name | Skye Bioscience, Inc. | source · 2026-11-08 |
| exchange | NASDAQ | source · 2026-11-08 |
| ticker | SKYE | source · 2026-11-08 |
| ISIN | not on the record | |
| LEI | not on the record | |
| security type | Corporate | source · 2026-11-08 |
| segment | not on the record | |
| sector | 2834 Pharmaceutical Preparations | source · 2026-11-08 |
| jurisdiction | United States — Nevada | source · 2026-11-08 |
| status | listed, not halted | source · 2026-11-08 |
The disclosure read
The record holds 64 filings across 30 filing days in the window 2025-11-08 to 2026-11-08. The median gap between filing days is 8 days. The median latency is 11 days from the latest filing to the record date of 2026-11-08. The latest filing is dated 2026-10-28 and is of type regulatory_filing. The NASDAQ median is 6.0 days for cadence, 52 filings and 5.0 days for latency across 4,359 issuers. The sector median is 6.0 days for cadence, 63.0 filings and 4.0 days for latency across 526 issuers.
| filings | median gap between filing days | days from latest filing to as-of | |
|---|---|---|---|
| this issuer | 64 | 8 | 11 |
| exchange median: NASDAQ (4359 issuers) | 52 | 6 | 5 |
| sector median: 2834 Pharmaceutical Preparations (526 issuers) | 63 | 6 | 4 |
| date | type | category | filing |
|---|---|---|---|
| 2026-10-28 | regulatory_filing | PRER14A | PRER14A — PRER14A |
| 2026-10-26 | regulatory_filing | PREM14A | PREM14A — PREM14A |
| 2026-10-14 | regulatory_filing | SCHEDULE 13G | SCHEDULE 13G |
| 2026-09-24 | regulatory_filing | SCHEDULE 13D/A | SCHEDULE 13D/A |
| 2026-09-24 | directors_dealings | 4 | 4 |
window 2025-11-08 to 2026-11-08 · the node's disclosure lines, as get_filings serves them
Auditor
The auditor of record is CBIZ CPAs P.C., located in Morristown, New Jersey. The record holds no auditor changes.
Events and halts
The record holds no listing, delisting or name change lines. The domicile change is not on the record, because EDGAR states no dated change of state of incorporation on a filing line. The segment move is not on the record, because the exchanges' tier transfers are not EDGAR filings. The halt flag reads listed, not halted.
Orderability
The outcome is not determinable. The chapter's orderability section carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04.
rule acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1 · chapter as of 2026-11-04 · the full outcome: get_orderability
Coverage
The record names 8 research houses on the issuer's investor-relations page: Cantor Fitzgerald, Citizens JMP, Craig-Hallum Capital Group, Evercore ISI, H.C. Wainwright & Co., Oppenheimer & Co., Piper Sandler and William Blair.
| research house | analyst | source · read date |
|---|---|---|
| Cantor Fitzgerald | Kristen Kluska | issuer page · 2026-11-11 |
| Citizens JMP | Jonathan Wolleben | issuer page · 2026-11-11 |
| Craig-Hallum Capital Group | Albert G Lowe, Ph.D. | issuer page · 2026-11-11 |
| Evercore ISI | Michael DiFiore, Pharm.D. | issuer page · 2026-11-11 |
| H.C. Wainwright & Co. | Ananda Ghosh, Ph.D. | issuer page · 2026-11-11 |
| Oppenheimer & Co. | Jay Olson | issuer page · 2026-11-11 |
| Piper Sandler | Ted Tenthoff | issuer page · 2026-11-11 |
| William Blair | Andy Hsieh, Ph.D. | issuer page · 2026-11-11 |
Open research
No openly published research notes were found on the record.
Licensed
Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.
| licensor | entitlement | title | date | source |
|---|---|---|---|---|
| none loaded |
As-of depth
The sealed years that hold the issuer are 2021, 2022, 2023, 2024, 2025 and 2026. The earliest sealed date of the market is 2021-01-04. The live record began on 2026-09-12.
Sources
8 source pages are named on this page; every value above carries its own source page and read date in the numbers.
- 10.1
- https://www.sec.gov/files/company_tickers_exchange.json (identity.exchange)
- 10.2
- https://data.sec.gov/submissions/CIK0001516551.json (identity.jurisdiction)
- 10.3
- https://mcp.us-cm-kg.ai/events/NASDAQ/SKYE (the disclosure lines)
- 10.4
- https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts (the halt flag)
- 10.5
- https://www.sec.gov/Archives/edgar/data/1516551/000162828026016394/skye-20251231.htm (the auditor)
- 10.6
- https://mcp.us-cm-kg.ai/book/aio.json (the orderability chapter)
- 10.7
- https://ir.skyebioscience.com/stock-data/analyst-coverage (coverage)
- 10.8
- https://mcp.us-cm-kg.ai/record/NASDAQ/SKYE (the record)
Read it by agent
The same page, signed and receipted: get_research at https://mcp.getresearch.ai/mcp with {"ticker":"SKYE","exchange":"NASDAQ"}. Twins: .md · .json. Written: Claude through the platform account, Haiku class; one pass; checked against the numbers. Page hash sha256:d9dd874a48021ff3.